U.S. Stock News

NasdaqGS:ITRN
NasdaqGS:ITRNCommunications

Ituran Location And Control (ITRN) Could Be 25% Undervalued Following Vulcan Backing

Ituran Location and Control (ITRN) drew fresh investor attention after Vulcan Value Partners highlighted the stock in its Q2 2026 letter, citing what it described as strong Q1 results and contributions from long-term agreements with Stellantis, Renault, and BMW. See our latest analysis for Ituran Location and Control. Despite the latest Q1 update and the Vulcan Value Partners endorsement, Ituran Location and Control’s recent 30 day share price return is down 9.35%, while the year to date...
NYSE:GBCI
NYSE:GBCIBanks

Glacier Bancorp (GBCI) Posted Stronger Earnings, Is It Still 13% Below Fair Value?

Glacier Bancorp (GBCI) has drawn fresh attention after reporting second quarter 2026 results, with higher net interest income and net income, alongside an increase in net charge-offs tied to overdrafts and loans. See our latest analysis for Glacier Bancorp. Glacier Bancorp's mixed recent share price performance, with a 1-day share price return of 0.65% but a 30-day share price return down 6.56%, contrasts with a stronger 1-year total shareholder return of 18.27%. This indicates that longer...
NYSE:KN
NYSE:KNElectronic

Will Stronger Q2 Results and Completed Buybacks Change Knowles' (KN) Capital Allocation Narrative?

In the second quarter of 2026, Knowles Corporation reported higher sales and earnings compared with a year earlier, issued revenue and EPS guidance for the third quarter, and completed a multi‑year share repurchase program totaling 15,638,913 shares for US$294.07 million. Together, the improved profitability and ongoing capital return through buybacks highlight how Knowles is pairing earnings growth with an actively managed share base. We’ll now examine how Knowles’ stronger quarterly...
NYSE:PB
NYSE:PBBanks

Should Prosperity’s Earnings Beat, Buyback and M&A Ambitions Require Action From Prosperity Bancshares (PB) Investors?

In late July 2026, Prosperity Bancshares, Inc. reported higher second-quarter and year-to-date earnings, modest net charge-offs of US$2.2 million, completion of a US$70.75 million share repurchase program, and affirmed a US$0.60 quarterly dividend payable on October 1, 2026. Management also highlighted continued discussions around future bank acquisitions while prioritizing the integration of three recently acquired banks, underscoring both growth ambitions and execution risk. We’ll now...
NasdaqGS:ICUI
NasdaqGS:ICUIMedical Equipment

ICU Medical (ICUI) Could Be 2% Undervalued As Recall Questions Meet A Full P E

ICU Medical (ICUI) is in focus after US regulators published enforcement reports on voluntary Class II recalls of its Plum Duo and Plum Solo infusion pumps, citing a software issue affecting displayed dosing volumes. See our latest analysis for ICU Medical. The US Food and Drug Administration recall news lands against a backdrop of strong recent momentum in ICU Medical's share price, with a 30 day share price return of 13.51% and a 1 year total shareholder return of 32.27%, even as the 5 year...
NYSE:NTB
NYSE:NTBBanks

Butterfield (NTB) Stock Still Looks Discounted Following Acquisition Cost Hit

Bank of N.T. Butterfield & Son has delivered a very strong 5 year return while the valuation checks still flag the stock as screening cheap on several measures. After that kind of run, investors are asking whether the current price still leaves room for a reasonable margin of safety. Over the past 5 years, Bank of N.T. Butterfield & Son has returned about 130%, which puts fresh focus on whether the current share price already reflects that value creation. The planned acquisition of CIBC...
NYSE:BABA
NYSE:BABAMultiline Retail

Is Alibaba Group Holding (BABA) Undervalued After Its Moonshot AI Cloud Deal?

Alibaba Group Holding (NYSE:BABA) is back in focus after reports of a major cloud deal supplying Moonshot AI with computing power equivalent to about 20,000 Nvidia chips. This development is drawing investor attention to its AI exposure. See our latest analysis for Alibaba Group Holding. Alibaba Group Holding's share price has reacted strongly to the Moonshot AI headlines, with a 1-day share price return of 5.10% and a 30-day share price return of 24.76%. However, the year to date share price...
NYSE:HTH
NYSE:HTHBanks

Can Hilltop Holdings (HTH) Justify Its Valuation Following Results And Higher Shareholder Returns?

Hilltop Holdings (HTH) is back in focus after a busy July, with fresh quarterly results, a higher dividend, additional buyback capacity, and a closely watched shareholder vote drawing new attention to the stock. See our latest analysis for Hilltop Holdings. At a share price of $39.44, Hilltop Holdings has built steady momentum, with a year to date share price return of 16.34% and a 1 year total shareholder return of 36.27%. This points to improving sentiment around earnings, buybacks, and the...
NasdaqCM:AIRJ
NasdaqCM:AIRJMachinery

How AirJoule’s GE Vernova Showcase Deployment Could Shape AirJoule Technologies (AIRJ) Investors

AirJoule Technologies Corporation announced that its AirJoule Core atmospheric water generation system has been deployed at GE Vernova’s Advanced Research Center Frontier Campus in Niskayuna, New York, where it now operates as a live showcase producing pure distilled water from air for visiting customers and partners. This installation deepens the 50/50 joint venture between AirJoule and GE Vernova by giving industrial and data center stakeholders direct exposure to AirJoule’s sorption-based...
NYSE:GEV
NYSE:GEVElectrical

Nuclear Energy Stocks Powering AI Demand Investors May Want To Watch

Nuclear energy stocks are back in focus as investors look for power sources that are less tied to short term swings in fossil fuel prices and geopolitics. With inflation readings mixed across regions and energy driven price risks still on the radar, many are rethinking how they get exposure to long term electricity demand. The Nuclear Energy Stocks screener helps you quickly filter the sector, from uranium suppliers to reactor operators, so you can focus on liquid, listed companies rather...
NYSE:BLK
NYSE:BLKCapital Markets

BlackRock Stock And The Short Duration Shift Investors Are Watching

Confusing signals from Federal Reserve Chair Kevin Warsh and a 5.23% yield on the 30 year U.S. Treasury have pushed interest rate risk back to the top of your watchlist. Long duration bond ETFs like TLT are feeling the pressure, while shorter term exposure such as IEI is drawing more attention as investors reassess where they want interest rate risk. This article examines how that backdrop connects to short duration fixed income themes and highlights three stocks tied to this news that could...
NYSE:LTH
NYSE:LTHHospitality

Life Time Group Holdings (LTH) Is Up 6.5% After Raising 2026 Outlook And Accelerating Club Expansion – Has The Bull Case Changed?

Life Time Group Holdings, Inc. reported stronger results for the quarter and six months ended June 30, 2026, with revenue rising to US$866.00 million and net income to US$101.36 million in the quarter, while also raising full-year 2026 revenue and net income guidance. The company is pairing this earnings momentum with an accelerated rollout of 14 largely large-format clubs in 2026, nearly doubling new-club square footage versus recent years and underscoring its push toward premium,...
NasdaqGM:ALNT
NasdaqGM:ALNTElectrical

Allient (ALNT) After Falling Sales And EPS What Is The Valuation Narrative

Fresh scrutiny of Allient (ALNT) has been triggered by reports of declining sales and earnings per share over the past two years, along with persistently low returns on capital that are shaping the current investment debate. See our latest analysis for Allient. Despite the pressure on Allient’s fundamentals, the stock has kept strong momentum, with a year to date share price return of 57.36% and a 1 year total shareholder return of 130.59%, even after an 11.33% decline over the past month. If...
NYSE:TGT
NYSE:TGTConsumer Retailing

Target (TGT) Faces Fresh Lawsuit As Valuation Questions Return

Target (TGT) is facing fresh legal scrutiny after being named in a product liability lawsuit linked to recalled Nara Organics Whole Milk Organic Infant Formula that regulators have associated with a multi state infant botulism outbreak. See our latest analysis for Target. Against this legal backdrop, Target’s share price has a 7 day return of 5.64% and a 90 day return of 12.10%. The 1 year total shareholder return of 51.16% contrasts with a 5 year total shareholder return that is down 35.36%,...
NasdaqGS:AMAT
NasdaqGS:AMATSemiconductor

Is Lam Research's AI Surge Quietly Redefining Applied Materials' Competitive Moat (AMAT)?

In late July 2026, Applied Materials gained investor attention after peer Lam Research reported record quarterly revenue and stronger guidance, prompting expectations that sector-wide demand for semiconductor equipment linked to AI infrastructure remains robust. The reaction highlights how closely investors tie Applied Materials’ prospects to broader wafer-fab equipment spending trends and read-throughs from key peers’ results. Next, we’ll examine how Lam Research’s stronger outlook, and its...
NYSE:F
NYSE:FAuto

Ford (F) Pushes USMCA Overhaul To Take On Japanese And Korean Rivals

Ford Motor CEO Jim Farley has publicly called for an overhaul of the USMCA trade agreement to improve US automakers' competitiveness versus Japanese and South Korean rivals. Farley is engaging with US and regional officials on potential changes that could affect North American manufacturing and supply chains. Ford Motor, ticker NYSE:F, is bringing trade policy directly into the investment conversation with this push on USMCA. The stock closed at $14.68 and has returned 42.4% over the past...
NYSE:TRV
NYSE:TRVInsurance

Travelers Companies (TRV) Expands Life Sciences Coverage, Is It Still Overvalued?

Travelers Companies expansion and recent bond issuance Travelers Companies (TRV) recently completed the nationwide rollout of its Travelers Synergy product liability coverage for life sciences firms, while also issuing callable senior unsecured fixed rate notes due 2031 totaling about US$750 million. See our latest analysis for Travelers Companies. At a share price of US$374.36, Travelers Companies has had a mixed few days, with the 1-day share price return declining 0.43% and the 7-day share...
NasdaqGM:WVE
NasdaqGM:WVEPharmaceuticals

Wave Life Sciences (WVE) Is Down 5.2% After Wider Q2 Losses And RNA Editing Updates - What's Changed

In late July 2026, Wave Life Sciences reported Q2 2026 results showing sales of US$2.27 million versus US$8.70 million a year earlier, with net loss widening to US$69.36 million and basic loss per share from continuing operations at US$0.34. Despite weaker quarterly revenue, the company highlighted progress in its RNAi and RNA editing programs, including positive data for obesity candidate WVE-007 and preparations for an FDA meeting on a potential accelerated approval pathway for AATD...
NYSE:INSW
NYSE:INSWOil and Gas

International Seaways (INSW) Stock Looks Fairly Valued Following Its 8.6x Run

International Seaways stock has logged very strong returns over the past few years, and after that run the current checks suggest it no longer looks obviously cheap on valuation. Over the last 5 years, International Seaways has delivered a very large total return of about 8.6x, which sets a high bar for any further share price gains to be justified by fundamentals. Future cash flows and earnings can benefit if the company maintains capital discipline and steady fleet utilization, while any...
NasdaqCM:AXGN
NasdaqCM:AXGNMedical Equipment

Why Axogen (AXGN) Is Up 6.9% After Raising 2026 Revenue Guidance Despite First-Half Loss

In the second quarter of 2026, Axogen reported sales of US$69.73 million, up from US$56.66 million a year earlier, but moved from a net income of US$0.579 million to a net loss of US$1.52 million, with both basic and diluted loss per share from continuing operations at US$0.03. Despite higher losses for both the quarter and first half of 2026, Axogen raised its full-year 2026 revenue guidance to at least US$279 million, highlighting management’s increased confidence in the company’s top-line...
NasdaqGS:RVMD
NasdaqGS:RVMDBiotechs

Is Revolution Medicines (RVMD) Fully Valued Following Its FDA Filing Win?

Revolution Medicines (RVMD) is back in focus after the FDA accepted its New Drug Application for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma, following Phase 3 RASolute 302 survival and quality of life data. See our latest analysis for Revolution Medicines. At a share price of US$187.53, Revolution Medicines has seen the share price rise 34.45% over the past 90 days and 137.32% year to date, with a 1 year total shareholder return above 400%. This suggests...
NasdaqGS:LOPE
NasdaqGS:LOPEConsumer Services

Did Strong Q2 Earnings and Steady GCU Fees Just Shift Grand Canyon Education's (LOPE) Investment Narrative?

Grand Canyon Education, Inc. has already reported second-quarter 2026 results showing higher net income of US$45.85 million and diluted EPS of US$1.75, alongside updated guidance calling for full-year 2026 diluted EPS between US$9.93 and US$10.07. An interesting angle is management’s expectation that reduced annual service revenue under a revised Grand Canyon University agreement will have only an immaterial effect on operating income, even as hybrid enrollment grows strongly. Next, we’ll...
NasdaqGS:DMLP
NasdaqGS:DMLPOil and Gas

Does Dorchester Minerals’ (DMLP) Latest Cash Distribution Clarify Its Long-Term Income Strategy?

Dorchester Minerals, L.P. previously announced a second quarter 2026 cash distribution of US$1.272943 per common unit for activity through June 30, 2026, payable on August 13, 2026 to unitholders of record as of August 3, 2026. This relatively high quarterly payout underscores the partnership’s ongoing importance for investors who prioritize regular cash distributions from energy-related assets. Against this backdrop, we’ll explore how Dorchester Minerals’ latest cash distribution shapes its...
NYSE:ZTS
NYSE:ZTSPharmaceuticals

Michael Burry’s Shift Toward Zoetis’ Animal Health Focus Might Change The Case For Investing In ZTS

In recent weeks, Michael Burry increased his position in Zoetis, reflecting his preference for consumer and healthcare names over the AI-focused semiconductor sector. This portfolio shift draws fresh attention to Zoetis’ role as a pure-play animal health company, potentially highlighting its differentiated exposure versus high-profile technology trades. We’ll now explore how Burry’s increased stake interacts with Zoetis’ existing animal health growth thesis and affects its broader investment...